Sichuan Huiyu Pharmaceutical Co., Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-30
RECRUITING5
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +12.0 months). See all sponsors →
Open Sichuan Huiyu Pharmaceutical Co., Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Test product: HYP-2090PTSA NCT06243354 |
P1/2 | Recruiting | Safety; Tolerability | 257 | 2026-12 (+12 mo) |
| Test Product HY07121 NCT06639256 |
P1/2 | Recruiting | Safety; Tolerability | 258 | 2027-05-26 (+13 mo) |
| Test product HY0001a for injection NCT07069062 |
P1/2 | Recruiting | Solid Tumor | 261 | 2027-06 (+4 mo) |
| HY05350 for injection NCT07083323 |
P1/2 | Recruiting | Advanced Solid Tumor | 262 | 2028-03-31 |
| Test Product HY07121 for Injection (Subcutaneous) NCT07789327 |
P1/2 | Not yet recruiting | Safety; Tolerability | 254 | 2028-04 |
| Test Product HYP-6589 NCT06712680 |
P1/2 | Recruiting | Solid Tumor | 115 | 2028-04-10 (+21 mo) |